Date: 2011-03-30
Type of information: R&D agreement
Compound: small molecule hits against an undisclosed key drug target
Company: Graffinity (Germany) Shionogi (Japan)
Therapeutic area: undisclosed
Type agreement: R&D
Action mechanism:
Disease: undisclosed
Details: Graffinity Pharmaceuticals GmbH , a member of the NovAliX group of companies, has entered into a research collaboration with Shionogi & Co., Ltd. Under the terms of the agreement, Graffinity will receive technology access fees and payments for follow-up chemistry for the generation of various, novel small molecule hits against a key drug target.
Financial terms: Financial details of the transaction were not disclosed.
Latest news:
